Gene-Silencing Drug Wainua Fails Landmark ATTR-CM Trial in AstraZeneca Setback
AstraZeneca and Ionis said their gene-silencing drug Wainua (eplontersen) failed the Phase 3 CARDIO-TTRansform trial in transthyretin-mediated amyloid cardiomyopathy. The study enrolled 1,432 patients over 140 weeks and did not significantly reduce cardiovascular deaths or recurrent events vs placebo. AstraZeneca shares fell about 9% and Ionis about 21%.
How this was made
The 30-second read
Why it matters
The primary composite endpoint failed to show meaningful reduction versus placebo, ending Wainua’s path as a potential fourth approved ATTR-CM treatment and shifting investor focus toward existing stabilizers and Amvuttra.
Market read
A large, late-stage clinical failure with immediate equity reaction is a direct repricing event for TTR-silencing strategies and competitive dynamics in ATTR-CM.
What to watch
The article emphasizes stabilizer background redundancy, but does not detail safety, subgroup heterogeneity, or endpoint component behavior, which could matter for any future regulatory or label strategy.
Background
CARDIO-TTRansform was a Phase 3 trial of eplontersen (Wainua) in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), designed to test benefit on top of standard care.
Ticker impact
AstraZeneca disclosed Wainua (eplontersen) failed the Phase 3 CARDIO-TTRansform trial, driving an about 9% London-share drop.
Near-term downside bias versus peers; volatility likely as investors reprice probability of future ATTR-CM wins.
The article reports a large, Phase 3 failure with immediate share reaction and explicit commercial framing as a setback.
Ionis reported eplontersen failed the large Phase 3 CARDIO-TTRansform trial, with shares down about 21% intraday.
Sustained negative sentiment until alternative indications or pipeline catalysts offset the ATTR-CM setback.
The article ties the failure to a sharp intraday move and describes the drug as ending prospects as a fourth approved ATTR-CM treatment.
The article says Alnylam’s Amvuttra (vutrisiran) effectively inherits the RNA-targeting role as eplontersen exits the race.
Near-term upside bias and relative outperformance versus AZN/IONS as the competitive set narrows.
The article reports double-digit share surges for Alnylam after the announcement, but does not provide new Amvuttra data beyond prior trial results.
BridgeBio shares surged double digits after the Wainua failure, with the article framing Amvuttra as the remaining RNA-targeting option.
Short-term supportive tape action versus AZN/IONS; longer-term depends on acoramidis trajectory.
The article links the move to competitive dynamics rather than a fresh BridgeBio catalyst.
Market effects
Reprices the probability that adding TTR knockdown on top of stabilizers improves outcomes, potentially cooling enthusiasm for similar antisense/siRNA combination strategies in ATTR-CM.
Immediate repricing in UK-listed AstraZeneca and US-listed Ionis, with spillover into US biotech sentiment for RNA-targeting ATTR-CM players.
ATTR-CM is a global market; the failure reshapes global treatment sequencing expectations and competitive positioning across major regions.
Counterpoint
The nominal monotherapy subgroup signal (HR 0.71) suggests eplontersen could still have value in less-stabilizer-treated populations, so the market may be over-discounting future niche use.
Key entities
- companyAstraZeneca
Sponsor of Wainua (eplontersen) and reported a major Phase 3 setback with immediate share impact.
- companyIonis Pharmaceuticals
Co-disclosed the CARDIO-TTRansform failure and saw a sharp intraday selloff.
- drugWainua (eplontersen)
Ligand-conjugated antisense therapy targeting TTR mRNA via RNase H recruitment.
- drugAmvuttra (vutrisiran)
Approved RNA interference therapy for ATTR-CM, positioned as the remaining RNA-targeting option after Wainua’s failure.
- drugAttruby (acoramidis)
TTR stabilizer approved in late 2024, part of the stabilizer standard-of-care backdrop discussed in the article.
